CDKN2A and cancer: The Egger test showed low publication bias for p16INK4A promoter methylation in cancer patients versus control patients, and in cancer in relation to lymph node status and tumor histology (P = 0.011, P = 0.02, P = 0.015, respectively) (Tables 2 and 4).